|
End-of-day quote
Korea S.E.
2026-09-14
|
5-day change | 1st Jan Change | ||
| 16,270.00 KRW | -3.56% |
|
-10.90% | -71.66% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-21 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
Company Valuation: IntoCell, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 861,052 |
| Change | - |
| Enterprise Value (EV) 1 | 840,466 |
| Change | - |
| P/E | -77.1x |
| PBR | 34.8x |
| PEG | 48.66x |
| Capitalization / Revenue | 374,513,177x |
| EV / Revenue | - |
| EV / EBITDA | -88.2x |
| EV / EBIT | -81.6x |
| EV / FCF | -132x |
| FCF Yield | -0.76% |
| Dividend per Share 2 | - |
| Rate of return | - |
| EPS 2 | -744 |
| Distribution rate | - |
| Net sales | 2,299 |
| EBITDA 1 | -9,526 |
| EBIT 1 | -10,300 |
| Net income 1 | -10,603 |
| Net Debt 1 | -20,586 |
| Reference price 2 | 57,400.00 |
| Nbr of stocks (in thousands) | 15,001 |
| Announcement Date | 3/1/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 189M | |
| 31.04x | 5.6x | 16.76x | 1.05% | 45.48B | |
| -20.85x | 240.83x | -22.36x | -.--% | 43.68B | |
| 33.71x | 3.27x | 14.1x | -.--% | 43.09B | |
| 45.39x | 5.23x | 28.64x | -.--% | 39.4B | |
| 27.03x | 8.15x | 20.66x | 0.42% | 31.91B | |
| 33.41x | 5.47x | 24.85x | -.--% | 16.4B | |
| 23.57x | 2.06x | 8.94x | 1.13% | 14.24B | |
| 74.44x | 3.94x | 15.27x | -.--% | 13.28B | |
| Average | 30.97x | 34.32x | 13.36x | 0.33% | 27.52B | |
| Weighted average by Cap. | 26.17x | 46.68x | 11.79x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A287840 Stock
- Valuation IntoCell, Inc.
Select your edition
All financial news and data tailored to specific country editions
